JADPRO Live 2019 Activities
JADPRO Live 2018 Activities
Clinical Case Series
Roundtable Series: Multiple Myeloma
MPN Resource Center
APSHO Educator Modules
Learn more on this topic:
Overview of Immunotherapy
What are the mechanisms of action and adverse effects of these agents?
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Is programmed cell death ligand 1 (PD-L1) testing necessary?
When should you image patients to assess response to immunotherapy?
Why is pseudo-progression an important issue in patients on immune checkpoint inhibitors?
How do responses to immune checkpoint inhibitors differ from responses to chemotherapy?
What cancers are most likely to respond to immunotherapy?
How do you educate patients about the timing of early and latent side effects?
Copyright © 2010-2020 Harborside Press, LLC All rights reserved.
Bot trap - Don't go here
to learn more.